Rohto Pharmaceutical Lifts Earnings Outlook and Hikes Dividend on Strong Overseas Performance

The latest announcement is out from Rohto Pharmaceutical Co ( (JP:4527) ).

Rohto Pharmaceutical has raised its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, citing stronger-than-expected performance in Asia and the Americas during the third quarter and an anticipated continuation of this strength into the fourth quarter. The company now expects higher net sales, operating income, ordinary income, and profit attributable to owners of the parent than previously projected, supported in part by updated foreign exchange assumptions of 150 yen to the U.S. dollar and 20.82 yen to the Chinese yuan.

Alongside the earnings upgrade, Rohto announced an increase to its year-end dividend forecast, lifting the planned payout by 1 yen to 23 yen per share and setting the full-year dividend at 44 yen per share. Management framed the move as part of a policy to return profits to shareholders in line with business results, signaling confidence in the company’s earnings momentum and enhancing shareholder returns compared with the prior fiscal year.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2876.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

More about Rohto Pharmaceutical Co

Rohto Pharmaceutical Co., Ltd. is a Japan-based healthcare company listed on the TSE Prime that develops and markets pharmaceuticals, cosmetics, and related consumer health products. The group has a significant international presence, including strong operations across Asia and the Americas, positioning it to benefit from global demand for over-the-counter medicines and skincare products.

Average Trading Volume: 618,885

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen604.2B

Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.